Earnings & Valuation
This table shows a comparison of the revenue, earnings per share, and valuation between ADMA Biologics and Passage Bio.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ADMA Biologics | $330.24 million | 10.96 | -$28.24 million | ($0.02) | -781.00 |
| Passage Bio | N/A | N/A | -$102.06 million | ($1.53) | -0.38 |
ADMA Biologics has higher revenue and earnings than Passage Bio. ADMA Biologics also has a lower price-to-earnings ratio, making it more affordable than Passage Bio.
Risk & Volatility
ADMA Biologics has a beta of 0.62, suggesting lower volatility compared to the S&P 500. Passage Bio has a beta of 1.19, indicating higher volatility than the S&P 500.
Analyst Recommendations
This section provides current recommendations and price targets for ADMA Biologics and Passage Bio from MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ADMA Biologics | 0 | 0 | 3 | 1 | 3.25 |
| Passage Bio | 0 | 0 | 3 | 0 | 3.00 |
ADMA Biologics has a consensus price target of $15.50 with a potential downside of 0.77%. Passage Bio’s consensus price target is $8.33 with a potential upside of 1,316.03%. Analysts favor Passage Bio over ADMA Biologics due to the higher upside potential.
Profitability
This table compares the net margins, return on equity, and return on assets of ADMA Biologics and Passage Bio.
| Net Margins | Return on Equity | Return on Assets | |
| ADMA Biologics | 10.53% | 38.79% | 17.35% |
| Passage Bio | N/A | -70.74% | -52.29% |
Insider and Institutional Ownership
75.7% of ADMA Biologics shares are owned by institutional investors, while 53.5% of Passage Bio shares are owned by institutional investors. Insiders own 3.7% of ADMA Biologics shares and 4.3% of Passage Bio shares. High institutional ownership indicates confidence in long-term growth potential.
Summary
ADMA Biologics outperforms Passage Bio on 9 of the 13 factors compared between the two stocks.
About ADMA Biologics
ADMA Biologics, Inc. is a biopharmaceutical company that specializes in developing, manufacturing, and marketing plasma-derived biologics for immune deficiencies and infectious diseases. The company’s products are sold worldwide through various channels. ADMA Biologics is headquartered in Ramsey, New Jersey.
About Passage Bio
Passage Bio, Inc. is a genetic medicines company focused on developing gene therapies for central nervous system diseases. The company has strategic collaborations and is based in Philadelphia, Pennsylvania.
Receive News & Ratings for ADMA Biologics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ADMA Biologics and related companies with MarketBeat.com’s FREE daily email newsletter.
